Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials.

Cushman TR, Verma V, Khairnar R, Levy J, Simone CB 2nd, Mishra MV.

Oncotarget. 2019 Sep 24;10(54):5660-5668. doi: 10.18632/oncotarget.27177. eCollection 2019 Sep 24.

2.

Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.

Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, D'Ambrosio D.

Cureus. 2015 Dec 4;7(12):e395. doi: 10.7759/cureus.395.

3.

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. doi: 10.1016/j.ijrobp.2019.03.051. Epub 2019 Apr 6.

PMID:
30959121
4.

The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer.

Lin YW, Lin LC, Lin KL.

Front Oncol. 2014 Oct 31;4:278. doi: 10.3389/fonc.2014.00278. eCollection 2014.

5.

Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.

Kotecha R, Djemil T, Tendulkar RD, Reddy CA, Thousand RA, Vassil A, Stovsky M, Berglund RK, Klein EA, Stephans KL.

Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):960-964. doi: 10.1016/j.ijrobp.2016.02.009. Epub 2016 Feb 6.

PMID:
27302511
6.

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma.

Kim HJ, Phak JH, Kim WC.

Radiat Oncol J. 2016 Dec;34(4):260-264. doi: 10.3857/roj.2015.01571. Epub 2016 Jun 17.

7.

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).

Janowski E, Chen LN, Kim JS, Lei S, Suy S, Collins B, Lynch J, Dritschilo A, Collins S.

Radiat Oncol. 2014 Nov 15;9:241. doi: 10.1186/s13014-014-0241-3.

8.

Hypofractionation for clinically localized prostate cancer.

Hickey BE, James ML, Daly T, Soh FY, Jeffery M.

Cochrane Database Syst Rev. 2019 Sep 3;9:CD011462. doi: 10.1002/14651858.CD011462.pub2.

PMID:
31476800
9.

The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.

Ricco A, Manahan G, Lanciano R, Hanlon A, Yang J, Arrigo S, Lamond J, Feng J, Mooreville M, Garber B, Brady L.

Front Oncol. 2016 Aug 23;6:184. doi: 10.3389/fonc.2016.00184. eCollection 2016.

10.

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Mar 13;8:58. doi: 10.1186/1748-717X-8-58.

11.

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer.

Oliai C, Lanciano R, Sprandio B, Yang J, Lamond J, Arrigo S, Good M, Mooreville M, Garber B, Brady LW.

J Radiat Oncol. 2013 Mar;2(1):63-70. Epub 2012 Sep 12.

12.

Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.

Zelefsky MJ, Pinitpatcharalert A, Kollmeier M, Goldman DA, McBride S, Gorovets D, Zhang Z, Varghese M, Happersett L, Tyagi N, Hunt M.

Eur Urol Oncol. 2019 Oct 23. pii: S2588-9311(19)30147-6. doi: 10.1016/j.euo.2019.09.006. [Epub ahead of print]

PMID:
31668713
13.

A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.

Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A.

BMC Urol. 2013 Oct 17;13:49. doi: 10.1186/1471-2490-13-49.

14.

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.

Paydar I, Pepin A, Cyr RA, King J, Yung TM, Bullock EG, Lei S, Satinsky A, Harter KW, Suy S, Dritschilo A, Lynch JH, Kole TP, Collins SP.

Front Oncol. 2017 Feb 7;7:5. doi: 10.3389/fonc.2017.00005. eCollection 2017.

15.

Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.

Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, Ingrosso G.

Eur Urol Focus. 2017 Dec;3(6):538-544. doi: 10.1016/j.euf.2017.07.006. Epub 2017 Aug 8.

PMID:
28801240
16.

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.

Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):296-303. doi: 10.1016/j.ijrobp.2018.05.040. Epub 2018 Jun 1.

17.

Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.

Alongi F, Mazzola R, Fiorentino A, Corradini S, Aiello D, Figlia V, Gregucci F, Ballario R, Cavalleri S, Ruggieri R.

Strahlenther Onkol. 2019 Feb;195(2):113-120. doi: 10.1007/s00066-018-1338-7. Epub 2018 Jul 12.

PMID:
30003292
18.
19.

High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.

Pontoriero A, Iatì G, Mondello S, Midili F, Siragusa C, Brogna A, Ielo I, Anastasi G, Magno C, Pergolizzi S, De Renzis C.

Technol Cancer Res Treat. 2016 Feb;15(1):179-85. doi: 10.1177/1533034614566994. Epub 2015 Jan 13.

PMID:
25586517
20.

High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.

Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e615-23. doi: 10.1016/j.prro.2015.04.009. Epub 2015 Jun 6.

PMID:
26059509

Supplemental Content

Support Center